Last reviewed · How we verify
RC278
At a glance
| Generic name | RC278 |
|---|---|
| Also known as | RC278 For Injection |
| Sponsor | RemeGen Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RC278 CI brief — competitive landscape report
- RC278 updates RSS · CI watch RSS
- RemeGen Co., Ltd. portfolio CI